Stuart Madden, PhD, has over 30 years of experience in the pharmaceutical industry, working on drug development programmes from proof of concept through to commercialisation for new chemical entity (NCE) and 505(b)(2) products that have encompassed small molecules, biologics and combination products.

Dr Madden received his BSc degree in Chemistry and his PhD in Physical Chemistry from the University of Wales (Swansea, UK). He is a Chartered Chemist and Fellow of the Royal Society of Chemistry and a past special government employee for the US FDA’s Advisory Committee for Pharmaceutical Science and Clinical Pharmacology.